SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs7221412

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study

Despite large efforts trying to improve diagnostic and therapy of sepsis have been made over the last decade (e.g. initiation of the Surviving Sepsis Campaign, defining evidence based sepsis therapy bundles) the mortality of septic shock remains high and causes high socioeconomical burden of disease. The purpose of this pilot study is to evaluate the design and conduct of a projected full scale clinical trial.

NCT02044575 Septic Shock
MeSH: Shock, Septic Shock

Furthermore, polymorphisms such as rs7221412, a common polymorphism near period homolog 1 (PER1), was associated with the timing of activity rhythms and also showed a suggestive time-dependent relationship with both cerebral cortex and monocytes PER1 expression and an association with time of death (Lim ASP et al., 2012).

Primary Outcomes

Description: Circadian regulation by expression of clock genes

Measure: Assessment of circadian regulation

Time: These parameters are measured during intensive care unit stay, for a maximum of 3 days

Secondary Outcomes

Measure: Time on mechanical ventilation

Time: They are followed up until the end of intensive care unit stay - or, for a maximum of 28 days

Measure: Intensive care unit length of stay

Time: Participants will be followed for the duration of intensive care stay, an expected average of 4 weeks

Measure: Hospital length of stay

Time: Participants will be followed for the duration of intensive care stay, an expected average of 5 weeks

Measure: Simplified Acute Physiology Score (SOFA II)

Time: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.

Measure: Sequential Organ Failure Assessment (SOFA)

Time: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.

Measure: Therapeutic Intervention Scoring System (TISS-28)

Time: They are measured until the end of intensive care unit stay - or, for a maximum of 28 days.

Measure: Mortality

Time: 6 months after intensive care unit discharge

Measure: Light frequencies

Time: Light frequencies are measured until the end of intensive care unit stay - or, for a maximum of 28 days

Measure: Light levels (lux)

Time: Light levels are measured until the end of intensive care unit stay - or, for a maximum of 28 days

Measure: Cortisol

Time: This parameter is measured in ng/ml during intensive care unit stay, for a maximum of 3 days

Measure: Melatonin

Time: This parameter is measured in pg/ml during intensive care unit stay, for a maximum of 3 days

Description: Quality of life is measured by SF-36 questionnaire

Measure: Quality of life

Time: Up to 3 and 6 months

Description: Cognitive function is measured by Repeatable Battery for the Assessment of Neuropsychological Status

Measure: Cognitive function

Time: Up to 3 and 6 months

Description: Ncounter neuroinflammation and micro rna panel are analysed

Measure: Multiplex-Genexpression analysis

Time: These parameters are measured during intensive care unit stay, for a maximum of 3 days

Other Outcomes

Description: Nagalase Enzyme activity is expressed in nmol/min per Milliliter. Analysis is evaluated with the perioperative Nagalase results of 10 patients in the clinical trial Phydelio (EudraCT-No 2008-007237-47).

Measure: Nagalase enzyme activity

Time: This parameter is measured at the beginning of the investigation

Description: Venous return will be assessed after ICU admission by venous return pressure gradient (dVR)

Measure: Venous return

Time: This parameter is measured at the beginning of the investigation


HPO Nodes